Tactile Systems Technology, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US87357P1003
USD
26.81
0.66 (2.52%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Tactile Systems Technology, Inc. stock-summary
stock-summary
Tactile Systems Technology, Inc.
Pharmaceuticals & Biotechnology
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices for the treatment of chronic diseases at home. The Company is a manufacturer and distributor of the Flexitouch and Entre Systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition that is often an unintended consequence of cancer treatment, and the ACTitouch System, a medical device used to treat venous leg ulcers and chronic venous insufficiency. Its products deliver long-term treatment of chronic diseases. The Company provides its products for use in the home and sells them through vascular, wound and lymphedema clinics throughout the United States. The Company offers a platform to deliver at-home healthcare solutions throughout the United States. Its initial area of therapeutic focus is vascular disease, with a focus on advancing the care in treating lymphedema and chronic venous insufficiency.
Company Coordinates stock-summary
Company Details
1331 Tyler St NE Ste 200 , MINNEAPOLIS MN : 55413-1638
stock-summary
Tel: 1 612 35551001 443 2130500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 71 Schemes (36.91%)

Foreign Institutions

Held by 71 Foreign Institutions (11.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Peter Soderberg
Independent Chairman of the Board
Mr. Daniel Reuvers
President, Chief Executive Officer, Director
Ms. Sheri Dodd
Director
Ms. Deepti Jain
Director
Mr. William Burke
Independent Director
Mr. Raymond Huggenberger
Independent Director
Mr. Richard Nigon
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
79 Million
(Quarterly Results - Jun 2025)
Net Profit:
3 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 300 Million (Micro Cap)

stock-summary
P/E

14.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.28

stock-summary
Return on Equity

7.75%

stock-summary
Price to Book

1.54